Commentary · 21 Feb 2026
Conference abstractPublished 7 Mar 2019
Utilizing a foamy viral vector for engineering safer CD19CART cells
Biomedical Research Foundation of the Academy of Athens, Greece University of Thessaly, Greece Larisa University Hospital, Greece Ludwig Institute for Cancer Research, Switzerland Centre Hospitalier Universitaire Vaudois, Switzerland
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The recent advances in the field of Immuno-oncology has led to unprecedented clinical outcomes for several cancer patients and to the approval of CD19CAR cell based therapies both in the EU and the USA. In the clinical setting, gene delivery of CD19 Chimeric Antigen Receptors (CARs) in patient derived T-cells, has been achieved predominantly by the use of gamma-retroviral or lentiviral vectors. Despite their vast use in the field, these vectors however possess potential threat for patients due to the random integration events in the human genome and the possibility of mutagenesis. To address the safety issues in the delivery of CART cell therapies, we employed a spumaviral vector, namely Foamy Virus (FV) that has been credited with having safer properties for the host genome in gene therapy (3, 4). We used an FV vector to clone our CD19CAR cassette under the control of a human EF-1alpha promoter (FVCD19CAR). Peripheral blood was obtained from normal donors and T-cells were subsequently isolated from the buffy coat using magnetic beads. T-cells were transduced with our FVCD19CAR expressing vector and expanded for 1-2 weeks under cytokine stimulation before functional testing. RNA was extracted from FVCD19CART cells and the CD19CAR expression was verified by RT-PCR. We demonstrate the transduction of T-cells using FV-GFP vectors by flow cytometry. Functional evaluation of CART cells was performed in co-incubation assays with relevant CD19 expressing target cell line (Raji). CART cell activation was confirmed by a marked increase in cytokine levels as detected by Elisa in co-incubation assays. Moreover, we show increased cell death in FVCD19CART co-incubation assays compared to the control FV-GFP and non-transduced T-cells. Overall, our results indicate the feasibility of engineering safer CD19CART cells that retain their activation and in vitro tumor cell killing properties and could potentially be used as alternative vehicle for gene delivery. Recent Publications 1. Hacein-Bey-Abina S et al. (2003) LMO2 associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 302(5644):415-9. 2. Fischer A, et al. (2013) Gene therapy of primary T cell immuno deficiencies. Gene 525(2):170-3. 3. Trobridge G D, et al. (2006) Foamy virus vector integration sites in normal human cells. PNAS. 103(5):1498-503. 4. Jonah D Hocum, et al. (2016) Retargeted foamy virus vectors integrate less frequently near proto-oncogenes. Sci Rep. 6:36610.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cancer Science & Therapy.
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Vasileios Atsaves”
- BylineArticles whose byline prints “Emmanouel Simantirakis”
- BylineArticles whose byline prints “Ioannis Tsironis”
- BylineArticles whose byline prints “Steven M Dunn”
- BylineArticles whose byline prints “George Vassilopoulos”

